Uğur Şahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)
November 3, 2023 01:18 PM EDT
Deals

Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

Ryan Cross

Senior Science Correspondent

BioN­Tech, the Ger­man drug com­pa­ny fa­mous for de­vel­op­ing a Covid-19 vac­cine with Pfiz­er, has ac­quired Aex­eR­NA and its nov­el lipid nanopar­ti­cles for mR­NA med­i­cines, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times